Uriconorm

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uriconorm

Quick Facts

Property Description
Active ingredient Allopurinol
Form Oral Tablet
Pharmacological class Xanthine Oxidase Inhibitor
General purpose Reduction of Uric Acid Production
Origin Synthetic Compound (Purine Analogue)

What Type of Medicine is Uriconorm?

Uriconorm is a pharmaceutical product primarily containing the active ingredient Allopurinol, which is categorized pharmacologically as a Xanthine Oxidase Inhibitor. This classification means it works by obstructing a key enzyme involved in the creation of uric acid within the body, a mechanism supported by pharmacological studies. Allopurinol is a widely recognized INN and a synthetic compound derived as a purine analogue, a structure that dictates its highly targeted action within the metabolic pathway. Uriconorm is marketed under a trade name but delivers the established efficacy of Allopurinol, which is clinically recognized for its role in managing chronic hyperuricemia. This single-ingredient product is consistently formulated as an Oral Tablet, the standard presentation for long-term systemic management.


What is the General Purpose of Uriconorm?

The general purpose of Uriconorm is to systematically reduce and maintain lower concentrations of uric acid in the blood and urine. Its core benefit is rooted in its mode of action: the inhibition of the xanthine oxidase enzyme provides a focused way to lower the overall metabolic burden of uric acid production. The medicine is characterized by its ability to lower serum uric acid levels effectively. The primary benefit is in providing reliable, long-term metabolic control by directly addressing the source of uric acid accumulation. The reduction of the uric acid load is vital for managing conditions stemming from abnormally high levels of this substance, known as hyperuricemia, and aids in the prevention of subsequent crystal formation in adult patients.

What side effects are possible with Uriconorm?

Possible side effects and safety information

The safety profile of Uriconorm (Allopurinol) is based on official government regulatory classifications, which organize potential effects by frequency and the body system affected. The most frequently documented adverse events are generally categorized as Common, while more severe reactions are designated as Rare or Very Rare.


Adverse Reaction Classification

Classification Examples of Reactions Systems Affected
Common Skin rash, Nausea, Vomiting, Diarrhea, Acute gout attacks (at initiation) Skin, Gastrointestinal, Hepatobiliary
Rare/Very Rare Severe Cutaneous Adverse Reactions (SJS/TEN/DRESS), Myelosuppression, Vasculitis Immune System, Blood, Skin, Hepatobiliary

Key Safety Patterns and Regulatory Notes

Official prescribing information notes that skin rash is the most common adverse reaction, and regulatory documents mandate that the medicine must be stopped immediately at the first appearance of a rash or any sign of a severe allergic reaction. The most serious risks documented are the Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Population-specific safety considerations are documented for certain groups. Patients with decreased renal function require reduced dosage due to an increased risk of severe adverse effects. Furthermore, individuals of Han Chinese, Thai, or Korean descent are recognized as having a higher genetic risk of developing SCARs.

Regarding timing, the increase in acute gout attacks is commonly reported during the early stages of Uriconorm administration. The overall safety structure separates common, expected events from the rare, severe systemic risks, ensuring that attention is drawn to the high-level safety constraints of the medication.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Uriconorm (Allopurinol) requires immediate professional medical attention. Official regulatory documents outline specific manifestations and mandated emergency procedures for overexposure.

Documented Manifestations

Overexposure may present with gastrointestinal and neurological signs, including nausea, vomiting, diarrhea, dizziness, and somnolence. Critical toxicity primarily involves the renal system, where massive overexposure has been associated with acute kidney failure, uremia, and the formation of crystals in the urine (crystalluria). Irreversible renal damage and, in rare severe cases, coma are listed as potential life-threatening outcomes. The severity of these effects may be increased in patients with pre-existing renal impairment.

Mandated Emergency Actions

It is a regulatory requirement to seek immediate medical attention or contact emergency services immediately upon suspicion of an overdose. The management strategy is strictly symptomatic and supportive, as no specific antidote is known for Allopurinol overexposure. To mitigate the risk of crystalluria and subsequent renal damage, maintaining adequate diuresis and enhanced fluid intake is a required procedural step. In cases of severe toxicity, regulatory information states that hemodialysis may be considered to expedite the clearance of the compound and its metabolites.

Therapeutic Uses of Uriconorm

What Uriconorm Treats: Main Uses and Benefits

The primary therapeutic scope of Uriconorm (Allopurinol) is aligned with domains involving the management of excessive uric acid levels. Its clinical application commonly spans three main domains to manage conditions associated with systemic imbalance.

Key Therapeutic Applications

Uriconorm generally provides foundational support for chronic hyperuricemia, which may produce disruptive symptom manifestations. It is applied across conditions involving inflammatory or irritative states, primarily addressing recurrent gout attacks, managing tophi (crystalline deposits), and offering prophylaxis against uric acid kidney stones. Its application is generally relevant across conditions presenting with recurrent or episodic manifestations.

“By supporting the sustained management of uric acid levels, this medication helps ease the overall symptom burden associated with gout and related complications.”

By helping to reduce the overall uric acid burden, it assists with maintaining a sense of stability and provides supportive relief for recurrent acute attacks of joint pain, swelling, and redness, contributing to improved comfort. Furthermore, it supports the management of tophi, which may ease chronic discomfort, and is relevant for the prophylaxis of acute metabolic crises like Tumor Lysis Syndrome in high-risk patients.

Quick Fact Relief for Symptom Domain
Primary Goal Chronic control of uric acid levels.
Symptom Type Recurrent acute joint pain and inflammation.
Benefit Focus Supports functional stability and helps ease chronic discomfort.

Regulatory References

  1. NIH MedlinePlus overview of Allopurinol

Eligibility and Restrictions for Use

Who can and cannot use Uriconorm? — Official Regulatory Information

The eligibility for Uriconorm (a xanthine oxidase inhibitor) is defined by official regulatory documentation, which specifies both required conditions for use and strict prohibitions (contraindications).

Eligibility Scope

  • Populations for whom use is allowed: Adult patients with chronic hyperuricemia (excessive uric acid in the blood) who also have gout, and who have either responded inadequately to a maximally titrated dose of allopurinol or are intolerant to allopurinol.
  • Populations for whom use is contraindicated: Patients with a known hypersensitivity to Uriconorm or any of its ingredients; patients currently being treated with azathioprine or mercaptopurine.
  • Populations for whom use is restricted or not recommended: Use is not recommended for the treatment of asymptomatic hyperuricemia (high uric acid without gout symptoms). Use is not recommended in patients with markedly increased rates of urate formation, such as those with Lesch-Nyhan syndrome or malignant disease receiving cytotoxic therapy. Caution is advised in patients with a history of major cardiovascular disease (e.g., heart attack, stroke).

Age and Condition-Specific Eligibility

Category Regulatory Status
Pediatric Population Safety and efficacy have not been established in patients under 18 years of age.
Severe Renal Impairment Use requires caution and a dose limitation is imposed (e.g., maximum dose 40 mg daily)
Severe Hepatic Impairment Safety and efficacy have not been established; use requires caution.
Pregnancy/Lactation No adequate human data on infant risk; use is generally restricted to when the potential benefit outweighs the risk.

Connection to the Overall Eligibility Profile

The regulatory profile strictly dictates that Uriconorm is reserved for adult gout patients who meet specific criteria regarding their prior treatment failure or intolerance to allopurinol. Formal contraindications prohibit its use with specific medications (azathioprine, mercaptopurine) due to severe toxicity risks, and use is not recommended for conditions where urate production is extremely high or for patients who do not have symptomatic gout.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents categorize Uriconorm's interaction profile based primarily on its effect as a potent inhibitor of the Xanthine Oxidase (XO) enzyme.


Contraindicated Combinations

Co-administration of Uriconorm with certain medicines is contraindicated due to the high risk of severe toxicity stemming from significantly increased plasma concentrations of the co-administered drug. These substances are highly dependent on XO for their metabolism.

Classification Interacting Medicines
High Risk (Contraindicated) Azathioprine, Mercaptopurine, Theophylline

Other Documented Interactions

Other pharmacokinetic interactions have been studied and documented in regulatory labeling, primarily related to enzyme and exposure modifications. Uriconorm is known to be a weak inhibitor of the CYP2D6 enzyme.

Interacting Medicine Interaction Type and Relevance
Naproxen Increases Uriconorm exposure ( AUC, Cmax) but is not considered clinically significant.
Desipramine Minor increase in Desipramine exposure due to weak CYP2D6 inhibition.
Colchicine, Indomethacin, Hydrochlorothiazide No clinically significant changes in the concentrations of either drug.

Food and Administration Notes

Uriconorm may be administered without regard to food or antacid use. No specific timing or separation requirements are specified in the labeling for the administration of doses related to its interactions.

Mechanism of Action

Inhibiting Uric Acid Production

Uriconorm functions as an inhibitor targeting the Xanthine Oxidase (XO) enzyme, which is primarily located in the liver and intestinal mucosa. This enzyme is responsible for the final two steps of the purine catabolism pathway, oxidizing precursors (hypoxanthine and xanthine) into uric acid. By binding to and deactivating XO, the drug suppresses the synthesis of uric acid. This targeted inhibition causes a reduction in the overall concentration of uric acid circulating in the bloodstream.


Modulating Systemic Metabolic Balance

The systemic consequence of reduced production alters the purine catabolism pathway, shifting the metabolic flow away from creating the end-product. This modulation establishes a decreased plasma concentration of uric acid, resulting in a new equilibrium within the physiological system.


Mobilizing Existing Tissue Deposits

Sustained lowering of plasma uric acid creates a favorable concentration gradient. This gradient encourages existing crystalline urate deposits in tissues to re-dissolve back into the circulation. This mobilization action allows the stored substance to re-enter the plasma for subsequent renal excretion.

Dosage and Administration Information

The administration of Uriconorm (Allopurinol) is primarily via the oral tablet for long-term systemic management. Intravenous (IV) infusion is an alternative route for specific high-risk clinical scenarios when oral intake is not feasible.

Administration Principle Guidelines
Initial Dosing & Titration Therapy begins with a low initial dose (100 mg once daily) followed by a gradual titration process in weekly increments until the serum urate target is reached. The dose should not exceed the established 800 mg daily maximum.
Frequency and Division Oral doses of 300 mg or less are generally taken once daily. Total daily doses that exceed 300 mg must be divided into multiple administrations throughout the day.
Administration Conditions The oral tablet should be taken after a meal to minimize potential gastrointestinal irritation. A standard procedural condition is ensuring high fluid intake to maintain a daily urinary output of at least 2 liters.
Population Adjustment Dose reduction is required for patients with impaired kidney function. Specific dosing tables, often based on Creatinine Clearance rates, guide this adjustment.

The usage protocol is structured as a renal-function-dependent titration to find the correct maintenance amount, ensuring the maximum dose is not surpassed. If a dose is missed, patients are instructed not to double the dose during the next scheduled administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uriconorm

Evidence for Use in Chronic Gout and Hyperuricemia

The research base for Uriconorm's application in conditions was evaluated for chronic high uric acid levels (hyperuricemia) and is supported by multiple study types. Scientists have conducted both Randomized Controlled Trials (RCTs) and large, multi-year observational studies. These studies examined outcomes related to systemic imbalance, specifically monitoring the change in the Serum Uric Acid (SUA) concentration was examined in adults.

Studies report patterns related to measurements of the primary SUA biomarker levels across diverse populations. Research also explored outcomes linked to inflammatory or irritative states, such as the measured frequency of gout attacks and patient-reported outcomes describing perceived discomfort. Furthermore, studies explored morphological changes related to the size of tophi (crystalline deposits).

What remains uncertain is the full duration of these observed patterns. Existing studies provide limited insight into very long-term outcomes beyond five years for the majority of patients. Additionally, the certainty remains low regarding the direct association of these uric acid changes with the incidence of major cardiovascular events or mortality over extended periods, as reports from large-scale studies have shown mixed findings or heterogeneous results.


Evidence for Use in Acute Metabolic Prophylaxis

Uriconorm was evaluated in research exploring its role in prophylaxis against rapid, severe increases in uric acid, such as those related to Tumor Lysis Syndrome (TLS). The evidence base includes clinical trials that examined Uriconorm against other agents used for prophylaxis in these high-risk settings.

These acute-setting studies was studied for patients during periods of increased physiological strain. Research examined the achievement of plasma uric acid control during the high-risk window and studies monitored outcomes related to renal function markers. Historical evidence and regulatory reports describe the medicine’s long history of application for this prophylactic purpose.

What remains uncertain is the need for more recent, dedicated placebo-controlled RCTs specifically isolating Uriconorm's contribution to prophylaxis in the current clinical landscape. Comparative evidence is lacking in certain specific clinical scenarios.


Evidence for Use in Kidney Stone Prevention

Research examined outcomes when Uriconorm was applied in conditions where stone formation patterns were observed, specifically the recurring formation of kidney stones. The research landscape includes prospective clinical trials where stone recurrence rates were monitored, as well as large-scale retrospective studies examining patient outcomes over defined time intervals.

Studies report patterns related to a measured change in the recurrence rate of new stone formation in the observed patient populations over multi-year follow-up periods. Additionally, research highlighted changes measured in the concentration of urinary uric acid and other related metabolic factors. Regulatory bodies acknowledge research describing patterns in patients with recurrent stones who have high uric acid in the urine (hyperuricosuria).

Follow-up durations were limited in some recurrence studies. Data distinguishing the effects of Uriconorm in patients with pure uric acid stones versus those with calcium stones complicated by high urine uric acid may be less detailed in aggregate reviews, meaning that the results apply only to the populations studied.


Long-Term Studies and Follow-Up Data

The research has examined long-term outcomes to understand sustained change in outcomes beyond short-term trial periods. Long-term observational cohorts and extended-duration RCTs were evaluated in research exploring how systemic or functional imbalance is maintained over multiple years.

Studies describe how SUA levels evolved in the observed populations over these extended follow-up durations. However, the outcomes related to large-scale events, such as cardiovascular events and all-cause mortality, show patterns that were mixed across different major studies. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions regarding extended outcomes.


Evidence in Specific Patient Groups

Research examined populations when Uriconorm was observed in patients who have Chronic Kidney Disease (CKD) alongside their primary condition. These studies monitored outcomes related to physiological strain or stress markers, such as changes in eGFR and other markers of kidney function. Evidence in this group is often derived from cohorts or subgroup analyses within larger trials.

For other specific groups, such as pediatric patients or pregnant populations, data are still emerging, and certainty remains low. The available evidence describes what has been observed—and what is still uncertain—about these groups.


Areas of Uncertainty and Research Gaps

While Uriconorm has been studied for decades, certain areas within the evidence landscape require further clarification. The evidence quality varies across studies, and some research limitations exist, particularly concerning the follow-up durations for many of the initial RCTs.

The data for long-term outcomes related to cardiovascular disease and all-cause mortality are still emerging, and current findings were mixed. Subgroup findings are uncertain for several populations, and comparative evidence is lacking in certain clinical scenarios. Research is ongoing to better contextualize how patients reported their experience over very long periods and in diverse, real-world settings.

Key Studies & References Allopurinol (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Uriconorm (FAQ)


Q: How quickly does Uriconorm start working to lower uric acid?

According to official product information, the reduction in uric acid levels in your blood and urine generally begins within 2 to 3 days of starting treatment. However, the full, stable therapeutic effects may not be observed until the medication has been taken for a week or more.


Q: Is Uriconorm a maintenance drug, or is it only for acute attacks?

Uriconorm is indicated for the long-term treatment and prevention of symptomatic gout and chronic high uric acid levels (hyperuricemia). Regulatory documents specify that it should not be used to treat an acute or sudden gout attack, and it is not typically started immediately following a flare-up.


Q: Does Uriconorm cure gout, or just manage the symptoms?

The purpose of Uriconorm is to lower and maintain reduced concentrations of uric acid in the body, which helps prevent future gout attacks and related complications. Regulatory information indicates the product’s role is to manage the underlying condition, focusing on the long-term treatment and prevention of symptoms. The term 'cure' is not used in regulatory context.


Q: Is it normal to feel a bit nauseous when first starting Uriconorm?

Yes, nausea is listed as a common side effect in the official product labeling. Additionally, some people may experience a temporary increase in acute gout attacks during the initial stages of administration. Any persistent or bothersome side effects should be discussed with a healthcare professional.


Q: Can Uriconorm cause a rash, and is that serious?

Skin rash is reported as the most common adverse reaction associated with this medication. While a rash may be mild, official regulatory bodies mandate that Uriconorm must be stopped immediately at the first sign of any rash due to the risk of rare but severe skin reactions. This risk highlights why a rash, even seemingly mild, must be reported to a healthcare provider immediately.


Q: Are there any long-term side effects associated with Uriconorm use?

The drug's safety profile includes adverse reactions categorized by frequency, from Common to Very Rare, which are monitored during long-term use. Regulatory guidelines provide detailed information on the potential risks, and your health status and risks are typically monitored by a physician during extended therapy.


Q: What foods or supplements should I avoid while taking Uriconorm?

Official labeling does not list any specific foods or common supplements as contraindicated (forbidden) with Uriconorm. However, a mandatory procedural condition noted in the labeling is ensuring a high fluid intake to maintain a daily urinary output of at least 2 liters. This helps prevent the formation of kidney stones.


Q: How long will I typically need to stay on Uriconorm treatment?

Uriconorm is approved for the long-term systemic management of chronic hyperuricemia and symptomatic gout. For many individuals, this treatment is continuous to keep uric acid levels controlled over many years, but the precise duration of treatment is an individualized clinical decision.


Q: Why do doctors sometimes prescribe Uriconorm along with another medication?

Regulatory information notes that Uriconorm may be prescribed alongside medications like colchicine or non-steroidal anti-inflammatory drugs (NSAIDs). This is often done at the start of therapy because the medication can temporarily precipitate or trigger an acute gout attack.


Q: Are there any studies comparing the effectiveness of Uriconorm to lifestyle changes alone?

Official guidelines indicate that mild cases of high uric acid without symptoms may be managed with fluid and dietary modifications alone. This establishes a clinical distinction where Uriconorm is generally reserved for symptomatic patients who require medication in addition to or instead of lifestyle changes.


Q: What does the latest research say about Uriconorm's success rate?

Clinical trials and observational studies show that Uriconorm is effective in achieving the goal of lowering Serum Uric Acid (SUA) concentrations. Studies consistently report patterns of SUA reduction and a measured decrease in the frequency of gout attacks in treated patients.


Q: Is Uriconorm available as a generic, or is it only branded?

Uriconorm is a brand name for the active ingredient Allopurinol. Allopurinol is a long-established drug that is widely available in generic form. Both the branded product and the generic versions are used clinically.


Q: Why do some people experience a temporary flare-up when they first start Uriconorm?

Regulatory documents confirm that an increase in acute gout attacks is a common event during the early stages of starting the medication. This temporary increase can be due to the drug mobilizing existing uric acid crystals from the tissues.


Q: Does Uriconorm need to be taken with food, or can I take it on an empty stomach?

Official administration conditions state that the tablet should be taken after a meal. This practice is recommended to minimize any potential irritation to the gastrointestinal system.


Q: What type of monitoring (blood tests) is required while taking Uriconorm?

A healthcare provider will use blood tests to monitor serum uric acid (SUA) concentrations to ensure the appropriate dose is maintained. Monitoring of liver function tests and kidney function may also be recommended, particularly when treatment is initiated or a dose change occurs.


Q: Is Uriconorm safe for people with diabetes?

Diabetes is listed in official labeling as a pre-existing medical condition that should be considered when the drug is used. All existing health conditions, including diabetes, are considered by a prescribing healthcare provider.


Q: Can Uriconorm cause headaches or dizziness?

Yes, regulatory documents list both headache and dizziness as reported side effects. Any concerning effects should be discussed with a healthcare provider.


Q: Is Uriconorm safe for teenagers or children?

For the treatment of gout and kidney stones, the safety and efficacy have not been established in patients under 18 years of age. Use in children is generally limited to specific, specialized indications, such as high uric acid levels due to cancer therapy.


Q: How does Uriconorm affect the kidneys over the long term?

Uriconorm and its metabolites are mainly eliminated from the body by the kidneys. For patients with existing impaired kidney function, mandatory dose reductions are required to lower the risk of side effects. The appropriate dosage is determined by a physician based on an individual's kidney health.


Q: What should I do if the side effects of Uriconorm become bothersome?

A rash or sign of a severe allergic reaction necessitates stopping the medication immediately and seeking emergency medical attention. For side effects that are bothersome but not severe, such as digestive issues, consulting with a healthcare professional is generally recommended.


Q: Is Uriconorm appropriate for elderly patients?

Regulatory information indicates that the drug can be used in the elderly. However, because older adults may have age-related deterioration in kidney function, a dose reduction may be required. The appropriate dosage is determined by a physician, who will consider the individual's kidney health.


Q: Are there any known issues with Uriconorm and liver function?

Liver disease requires caution, and a reduced dose should be used in patients with impaired hepatic (liver) function. The official label notes the potential for liver damage as a serious side effect, and periodic monitoring of liver function tests may be part of the recommended care.


Q: Can Uriconorm affect my sleep or cause insomnia?

Drowsiness (somnolence) is a reported adverse effect. Caution is advised when engaging in activities that require mental alertness, such as driving or operating machinery.


Q: What happens if I accidentally take more Uriconorm than prescribed?

If an overdose is suspected, emergency medical attention should be sought immediately. Regulatory documents state that massive absorption can cause symptoms including nausea, vomiting, dizziness, and diarrhea, and can interfere with other medications.


Q: Can Uriconorm be crushed or split if I have trouble swallowing pills?

Official labeling does not provide instructions or guidance for crushing or splitting the tablets. Unless instructions for crushing or splitting are specifically provided by a healthcare professional, tablets are generally intended to be swallowed whole.


Q: Are there warnings about Uriconorm use in people with specific genetic conditions?

Yes, regulatory warnings note that individuals who carry the *HLA-B58:01 allele** are at a higher risk of developing severe skin reactions. Genetic screening may be considered in high-prevalence groups to assess this risk.


Q: Can Uriconorm cause stomach upset or diarrhea?

Yes, diarrhea, nausea, and vomiting are listed as common side effects of Uriconorm. Taking the medication after a meal is one way to help minimize irritation in the stomach and digestive system.


Q: Can I drive or operate machinery after taking Uriconorm?

Due to the occasional risk of drowsiness, caution is advised when engaging in activities that require mental alertness, such as driving or operating machinery. This caution is maintained until the individual knows how the drug affects them.


Q: Is Uriconorm known to cause any weight changes (gain or loss)?

Regulatory documents list weight loss (anorexia) as an infrequently reported adverse effect. Any unexpected weight changes or related systemic symptoms should be discussed with a healthcare professional for evaluation.

How should Uriconorm be stored and disposed of?

How to Store and Dispose of Uriconorm?

This section outlines the official, label-based requirements for storing and discarding Uriconorm (Allopurinol) tablets, as specified by government regulatory authorities.

Storage Conditions

Requirement Details (Regulatory Labeling)
Temperature Store at room temperature, typically defined as below 30 C (or 25 C in some regions).
Protection Mandatory to protect the tablets from excessive heat, moisture, and direct light. Do not freeze.
Packaging Keep the medicine in its original container and ensure the container is tightly closed when not in use.
Safety Rule Keep Uriconorm strictly out of the sight and reach of children.

Disposal Instructions

Official disposal guidance states that unused, expired, or unwanted medicine must not be discarded into household waste, wastewater, or down a sink. Individuals should consult a healthcare professional, pharmacist, or local waste disposal service for instructions on established take-back programs or safe disposal procedures for outdated pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uriconorm found in:

A-Z Index: